Table 4.

Multivariate analysis of chronic GVHD for patients surviving at least 90 days




Relative risk of chronic GVHD (95% CI)

P
HLA-identical sibling BM   
   G-CSF+ within 7 days after transplantation vs no G-CSF*  1.10 (0.86-1.39)   .13  
   Age   1.03 (1.02-1.03)   < .001  
   Other D/R sex combination vs F D/M R*  0.63 (0.51-0.77)   .001  
   CML vs AML*  1.36 (1.12-1.66)   .002  
   Year of transplantation    
      1999 to 2000 vs 1995-1996*  0.48 (0.35-0.67)   < .001  
HLA-identical sibling PBSCs   
   G-CSF+ within 7 days after transplantation vs no G-CSF*  1.24 (0.94-1.63)   .11  
   Year of transplantation, 1997 to 1998 vs 1995 to 1996*  0.67 (0.48-0.93)   .02  
      1999 to 2000 vs 1995 to 1996*  0.67 (0.49-0.94)   < .001  
   KPS more than 80* vs less than 80%   0.65 (0.46-0.92)   .01  
Matched unrelated donor BM   
   G-CSF+ within 7 days after transplantation vs no G-CSF*  0.85 (0.63-1.15)   .30  
   CML vs AML*  1.45 (1.05-2.01)   .03  
   Recipient CMV status, negative vs positive*
 
0.66 (0.49-0.89)
 
.007
 



Relative risk of chronic GVHD (95% CI)

P
HLA-identical sibling BM   
   G-CSF+ within 7 days after transplantation vs no G-CSF*  1.10 (0.86-1.39)   .13  
   Age   1.03 (1.02-1.03)   < .001  
   Other D/R sex combination vs F D/M R*  0.63 (0.51-0.77)   .001  
   CML vs AML*  1.36 (1.12-1.66)   .002  
   Year of transplantation    
      1999 to 2000 vs 1995-1996*  0.48 (0.35-0.67)   < .001  
HLA-identical sibling PBSCs   
   G-CSF+ within 7 days after transplantation vs no G-CSF*  1.24 (0.94-1.63)   .11  
   Year of transplantation, 1997 to 1998 vs 1995 to 1996*  0.67 (0.48-0.93)   .02  
      1999 to 2000 vs 1995 to 1996*  0.67 (0.49-0.94)   < .001  
   KPS more than 80* vs less than 80%   0.65 (0.46-0.92)   .01  
Matched unrelated donor BM   
   G-CSF+ within 7 days after transplantation vs no G-CSF*  0.85 (0.63-1.15)   .30  
   CML vs AML*  1.45 (1.05-2.01)   .03  
   Recipient CMV status, negative vs positive*
 
0.66 (0.49-0.89)
 
.007
 

BM indicates bone marrow; G-CSF, granulocyte colony stimulating factor; D, donor; R, recipient; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; PBSC, peripheral blood stem cell; KPS, Karnofsky performance status; and CMV, cytomegalovirus.

*

Reference group

Close Modal

or Create an Account

Close Modal
Close Modal